Publications

• 1. Uccello TP
  2. Lesch ML
  3. Kintzel SA
  4. Gradzewicz LB
  5. Lamrous L
  6. Murphy SP
  7. Fleming FJ
  8. Mills BN
  9. Murphy JD
  10. Hughson A
  11. Hannon G
  12. Garrett-Larsen J
  13. Qiu H
  14. Drage MG
  15. Ye J
  16. Gavras NW
  17. Keeley DC
  18. Love TMT
  19. Repasky EA
  20. Lord EM
  21. Linehan DC
  22. Gerber SA
  New insights into the responder/nonresponder divide in rectal cancer: Damage-induced Type I IFNs dictate treatment efficacy and can be targeted to enhance radiotherapy.; Cell death & disease; Vol 14(7), pp. 470. 2023 Jul 26.
• 1. Ye J
  2. Gavras NW
  3. Keeley DC
  4. Hughson AL
  5. Hannon G
  6. Vrooman TG
  7. Lesch ML
  8. Johnston CJ
  9. Lord EM
  10. Belt BA
  11. Linehan DC
  12. Eyles J
  13. Gerber SA
  CD73 and PD-L1 dual blockade amplifies antitumor efficacy of SBRT in murine PDAC models.; Journal for immunotherapy of cancer; Vol 11(5). 2023 May.
• 1. Battaglia NG
  2. Murphy JD
  3. Uccello TP
  4. Hughson A
  5. Gavras NW
  6. Caldon JJ
  7. Gerber SA
  8. Lord EM
  Combination of NKG2A and PD-1 Blockade Improves Radiotherapy Response in Radioresistant Tumors.; Journal of immunology (Baltimore, Md. : 1950). 2022 Jul 15.
• 1. Ye J
  2. Mills BN
  3. Qin SS
  4. Garrett-Larsen J
  5. Murphy JD
  6. Uccello TP
  7. Han BJ
  8. Vrooman TG
  9. Johnston CJ
  10. Lord EM
  11. Belt BA
  12. Linehan DC
  13. Gerber SA
  Toll-like receptor 7/8 agonist R848 alters the immune tumor microenvironment and enhances SBRT-induced antitumor efficacy in murine models of pancreatic cancer.; Journal for immunotherapy of cancer; Vol 10(7). 2022 Jul.
• 1. Ortiz-Bonilla CJ
  2. Uccello TP
  3. Gerber SA
  4. Lord EM
  5. Messing EM
  6. Lee YF
  Bladder Cancer Extracellular Vesicles Elicit a CD8 T Cell-Mediated Antitumor Immunity.; International journal of molecular sciences; Vol 23(6). 2022 Mar 08.
• 1. Uccello TP
  2. Kintzel SA
  3. Mills BN
  4. Murphy JD
  5. Garrett-Larsen J
  6. Battaglia NG
  7. Rodriguez CJ
  8. Drage MG
  9. Ye J
  10. Love TMT
  11. Johnston CJ
  12. Repasky EA
  13. Qiu H
  14. Linehan DC
  15. Lord EM
  16. Gerber SA
  Development of an Orthotopic Murine Model of Rectal Cancer in Conjunction With Targeted Short-Course Radiation Therapy.; Advances in radiation oncology; Vol 7(2). 2022 Mar.
• 1. Uccello TP
  2. Lecsh ML
  3. Ullman NA
  4. Kintzel SA
  5. Gradzewicz LB
  6. Velagaleti T
  7. Fleming FJ
  8. Mills BN
  9. Murphy JD
  10. Garrett-Larsen J
  11. Qiu H
  12. Drage MG
  13. Ye J
  14. Gavras NW
  15. Johnston CJ
  16. Love TMT
  17. Repasky EA
  18. Linehan DC
  19. Lord EM
  20. Gerber SA
  Radiotherapy exacerbates tumor-promoting innervation and nerve signaling in rectal cancer.; International journal of radiation oncology, biology, physics. 2022 Jan 03.
• 1. Qin SS
  2. Han BJ
  3. Williams A
  4. Jackson KM
  5. Jewell R
  6. Chacon AC
  7. Lord EM
  8. Linehan DC
  9. Kim M
  10. Reuben A
  11. Gerber SA
  12. Prieto PA
  Intertumoral Genetic Heterogeneity Generates Distinct Tumor Microenvironments in a Novel Murine Synchronous Melanoma Model.; Cancers; Vol 13(10). 2021 May 11.
• 1. Battaglia NG
  2. Uccello TP
  3. Hughson A
  4. Garrett-Larsen J
  5. Caldon JJ
  6. Qiu H
  7. Gerber SA
  8. Lord EM
  Co-administration of a clinically relevant dexamethasone dosage with ablative radiotherapy reduces peripheral lymphocytes but does not alter in vivo intratumoral lymphocyte phenotype or inhibit efficacy of radiotherapy in a murine colorectal tumor model.; International journal of radiation oncology, biology, physics. 2021 Apr 29.
• 1. Han BJ
  2. Murphy JD
  3. Qin S
  4. Ye J
  5. Uccello TP
  6. Garrett-Larsen J
  7. Belt BA
  8. Prieto PA
  9. Egilmez NK
  10. Lord EM
  11. Linehan DC
  12. Mills BN
  13. Gerber SA
  Microspheres Encapsulating Immunotherapy Agents Target the Tumor-Draining Lymph Node in Pancreatic Ductal Adenocarcinoma.; Immunological investigations. 2020 Jun 04.
• 1. Ye J
  2. Mills BN
  3. Zhao T
  4. Han BJ
  5. Murphy JD
  6. Patel AP
  7. Johnston CJ
  8. Lord EM
  9. Belt BA
  10. Linehan DC
  11. Gerber SA
  Assessing the magnitude of immunogenic cell death following chemotherapy and irradiation reveals a new strategy to treat pancreatic cancer.; Cancer immunology research. 2019 Nov 12.
• 1. Mills BN
  2. Connolly KA
  3. Ye J
  4. Murphy JD
  5. Uccello TP
  6. Han BJ
  7. Zhao T
  8. Drage MG
  9. Murthy A
  10. Qiu H
  11. Patel A
  12. Figueroa NM
  13. Johnston CJ
  14. Prieto PA
  15. Egilmez NK
  16. Belt BA
  17. Lord EM
  18. Linehan DC
  19. Gerber SA
  Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.; Cell reports; Vol 29(2). 2019 Oct 08.
• 1. Murthy A
  2. Gerber SA
  3. Koch CJ
  4. Lord EM
  Intratumoral Hypoxia Reduces IFN-γ-Mediated Immunity and MHC Class I Induction in a Preclinical Tumor Model.; ImmunoHorizons; Vol 3(4). 2019 Apr 29.
• 1. MacDonald CR
  2. Bucsek MJ
  3. Qiao G
  4. Chen M
  5. Evans L
  6. Greenberg DJ
  7. Uccello TP
  8. Battaglia NG
  9. Hylander BL
  10. Singh AK
  11. Lord EM
  12. Gerber SA
  13. Repasky EA
  Adrenergic Receptor Signaling Regulates the Response of Tumors to Ionizing Radiation.; Radiation research. 2019 Apr 25.
• 1. Connolly KA
  2. Belt BA
  3. Figueroa NM
  4. Murthy A
  5. Patel A
  6. Kim M
  7. Lord EM
  8. Linehan DC
  9. Gerber SA
  Increasing the efficacy of radiotherapy by modulating the CCR2/CCR5 chemokine axes.; Oncotarget. 2016 Nov 11.
• 1. Barlow ML
  2. Cummings RJ
  3. Pentland AP
  4. Love TM
  5. Haidaris CG
  6. Ryan JL
  7. Lord EM
  8. Gerber SA
  Total-Body Irradiation Exacerbates Dissemination of Cutaneous Candida Albicans Infection.; Radiation research. 2016 Oct 6.
• 1. Zozzaro-Smith PE
  2. Bushway ME
  3. Gerber SA
  4. Hebert D
  5. Pressman EK
  6. Lord EM
  7. Miller RK
  8. Murphy SP
  Whole mount immunofluorescence analysis of placentas from normotensive versus preeclamptic pregnancies.; Placenta; Vol 36(11). 2015 Nov.
• 1. Gerber SA
  2. Cummings RJ
  3. Judge JL
  4. Barlow ML
  5. Nanduri J
  6. Johnson DE
  7. Palis J
  8. Pentland AP
  9. Lord EM
  10. Ryan JL
  Interleukin-12 preserves the cutaneous physical and immunological barrier after radiation exposure.; Radiation research; Vol 183(1). 2015 Jan.
• 1. Martin DK
  2. Uckermann O
  3. Bertram A
  4. Liebner C
  5. Hendruschk S
  6. Sitoci-Ficici KH
  7. Schackert G
  8. Lord EM
  9. Temme A
  10. Kirsch M
  Differential growth inhibition of cerebral metastases by anti-angiogenic compounds.; Anticancer research; Vol 34(7). 2014 Jul.
• 1. Gerber SA
  2. Lim JY
  3. Connolly KA
  4. Sedlacek AL
  5. Barlow ML
  6. Murphy SP
  7. Egilmez NK
  8. Lord EM
  Radio-responsive tumors exhibit greater intratumoral immune activity than nonresponsive tumors.; International journal of cancer; Vol 134(10). 2014 May 15.
• 1. Bushway ME
  2. Gerber SA
  3. Fenton BM
  4. Miller RK
  5. Lord EM
  6. Murphy SP
  Morphological and phenotypic analyses of the human placenta using whole mount immunofluorescence.; Biology of reproduction; Vol 90(5). 2014 May.
• 1. Xu Y
  2. Hyun YM
  3. Lim K
  4. Lee H
  5. Cummings RJ
  6. Gerber SA
  7. Bae S
  8. Cho TY
  9. Lord EM
  10. Kim M
  Optogenetic control of chemokine receptor signal and T-cell migration.; Proceedings of the National Academy of Sciences of the United States of America; Vol 111(17). 2014 Apr 29.
• 1. Lim JY
  2. Gerber SA
  3. Murphy SP
  4. Lord EM
  Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8(+) T cells.; Cancer immunology, immunotherapy : CII; Vol 63(3). 2014 Mar.
• 1. Majumder S
  2. Sowden MP
  3. Gerber SA
  4. Thomas T
  5. Christie CK
  6. Mohan A
  7. Yin G
  8. Lord EM
  9. Berk BC
  10. Pang J
  G-protein-coupled receptor-2-interacting protein-1 is required for endothelial cell directional migration and tumor angiogenesis via cortactin-dependent lamellipodia formation.; Arteriosclerosis, thrombosis, and vascular biology; Vol 34(2). 2014 Feb.
• 1. Lim JY
  2. Brockstedt DG
  3. Lord EM
  4. Gerber SA
  Radiation therapy combined with Listeria monocytogenes-based cancer vaccine synergize to enhance tumor control in the B16 melanoma model.; Oncoimmunology; Vol 3. 2014.
• 1. Sedlacek AL
  2. Gerber SA
  3. Randall TD
  4. van Rooijen N
  5. Frelinger JG
  6. Lord EM
  Generation of a dual-functioning antitumor immune response in the peritoneal cavity.; The American journal of pathology; Vol 183(4). 2013 Oct.
• 1. Gerber SA
  2. Sedlacek AL
  3. Cron KR
  4. Murphy SP
  5. Frelinger JG
  6. Lord EM
  IFN-γ mediates the antitumor effects of radiation therapy in a murine colon tumor.; The American journal of pathology; Vol 182(6). 2013 Jun.
• 1. Gerber SA
  2. Sorensen EW
  3. Sedlacek AL
  4. Lim JY
  5. Skrombolas D
  6. Frelinger JG
  7. Lord EM
  Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy.; Immunology; Vol 138(3). 2013 Mar.
• 1. Cummings RJ
  2. Gerber SA
  3. Judge JL
  4. Ryan JL
  5. Pentland AP
  6. Lord EM
  Exposure to ionizing radiation induces the migration of cutaneous dendritic cells by a CCR7-dependent mechanism.; Journal of immunology (Baltimore, Md. : 1950); Vol 189(9). 2012 Nov 01.
• 1. Valentino MD
  2. Abdul-Alim CS
  3. Maben ZJ
  4. Skrombolas D
  5. Hensley LL
  6. Kawula TH
  7. Dziejman M
  8. Lord EM
  9. Frelinger JA
  10. Frelinger JG
  A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.; Journal of immunological methods; Vol 373(1-2). 2011 Oct 28.
• 1. Sorensen EW
  2. Gerber SA
  3. Frelinger JG
  4. Lord EM
  IL-12 suppresses vascular endothelial growth factor receptor 3 expression on tumor vessels by two distinct IFN-gamma-dependent mechanisms.; Journal of immunology (Baltimore, Md. : 1950); Vol 184(4). 2010 Feb 15.
• 1. Lord EM
  Immunology at the university of Rochester.; Immunologic research; Vol 45(2-3). 2009 Dec.
• 1. Sorensen EW
  2. Gerber SA
  3. Sedlacek AL
  4. Rybalko VY
  5. Chan WM
  6. Lord EM
  Omental immune aggregates and tumor metastasis within the peritoneal cavity.; Immunologic research; Vol 45(2-3). 2009 Dec.
• 1. Cummings RJ
  2. Mitra S
  3. Foster TH
  4. Lord EM
  Migration of skin dendritic cells in response to ionizing radiation exposure.; Radiation research; Vol 171(6). 2009 Jun.
• 1. Cummings RJ
  2. Mitra S
  3. Lord EM
  4. Foster TH
  Antibody-labeled fluorescence imaging of dendritic cell populations in vivo.; Journal of biomedical optics; Vol 13(4). 2008 Jul.
• 1. Lugade AA
  2. Sorensen EW
  3. Gerber SA
  4. Moran JP
  5. Frelinger JG
  6. Lord EM
  Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity.; Journal of immunology (Baltimore, Md. : 1950); Vol 180(5). 2008 Mar 1.
• 1. Santos K
  2. Simon DA
  3. Conway E
  4. Bowers WJ
  5. Mitra S
  6. Foster TH
  7. Lugade A
  8. Lord EM
  9. Federoff HJ
  10. Dewhurst S
  11. Frelinger JG
  Spatial and temporal expression of herpes simplex virus type 1 amplicon-encoded genes: implications for their use as immunization vectors.; Human gene therapy; Vol 18(2). 2007 Feb.
• 1. Ramanayake T
  2. Simon DA
  3. Frelinger JG
  4. Lord EM
  5. Robert J
  In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.; Transplantation; Vol 83(2). 2007 Jan 27.
• 1. Gerber SA
  2. Rybalko VY
  3. Bigelow CE
  4. Lugade AA
  5. Foster TH
  6. Frelinger JG
  7. Lord EM
  Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth.; The American journal of pathology; Vol 169(5). 2006 Nov.
• 1. Lugade AA
  2. Moran JP
  3. Gerber SA
  4. Rose RC
  5. Frelinger JG
  6. Lord EM
  Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor.; Journal of immunology (Baltimore, Md. : 1950); Vol 174(12). 2005 Jun 15.
• 1. Gerber SA
  2. Turner MJ
  3. Lugade AA
  4. Moran JP
  5. Frelinger JG
  6. Lord EM
  Characterization of a lymph node within the mouse prostate: Detailed analysis using whole mount histology.; The Prostate; Vol 63(2). 2005 May 1.
• 1. Moran JP
  2. Gerber SA
  3. Martin CA
  4. Frelinger JG
  5. Lord EM
  Transfection of the genes for interleukin-12 into the K1735 melanoma and the EMT6 mammary sarcoma murine cell lines reveals distinct mechanisms of antitumor activity.; International journal of cancer; Vol 106(5). 2003 Sep 20.
• 1. Gerber SA
  2. Moran JP
  3. Frelinger JG
  4. Frelinger JA
  5. Fenton BM
  6. Lord EM
  Mechanism of IL-12 mediated alterations in tumour blood vessel morphology: analysis using whole-tissue mounts.; British journal of cancer; Vol 88(9). 2003 May 6.
• 1. Fisher TL
  2. Nocera M
  3. Willis RA
  4. Turner MJ
  5. Abdul Alim CS
  6. Brown DM
  7. Bourne PA
  8. di Sant'Agnese PA
  9. Messing EM
  10. Lord EM
  11. Frelinger JG
  Generation of monoclonal antibodies specific for human kallikrein 2 (hK2) using hK2-expressing tumors.; The Prostate; Vol 51(3). 2002 May 15.
• 1. Willis RA
  2. Bowers WJ
  3. Turner MJ
  4. Fisher TL
  5. Abdul-Alim CS
  6. Howard DF
  7. Federoff HJ
  8. Lord EM
  9. Frelinger JG
  Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice.; Human gene therapy; Vol 12(15). 2001 Oct 10.
• 1. Turner MJ
  2. Abdul-Alim CS
  3. Willis RA
  4. Fisher TL
  5. Lord EM
  6. Frelinger JG
  T-cell antigen discovery (T-CAD) assay: a novel technique for identifying T cell epitopes.; Journal of immunological methods; Vol 256(1-2). 2001 Oct 1.
• 1. Fenton BM
  2. Lord EM
  3. Paoni SF
  Intravascular HBO(2) saturations, perfusion and hypoxia in spontaneous and transplanted tumor models.; International journal of cancer; Vol 93(5). 2001 Sep 1.
• 1. Brown DM
  2. Fisher TL
  3. Wei C
  4. Frelinger JG
  5. Lord EM
  Tumours can act as adjuvants for humoral immunity.; Immunology; Vol 102(4). 2001 Apr.
• 1. Fenton BM
  2. Lord EM
  3. Paoni SF
  Effects of radiation on tumor intravascular oxygenation, vascular configuration, development of hypoxia, and clonogenic survival.; Radiation research; Vol 155(2). 2001 Feb.
• 1. Lee J
  2. Moran JP
  3. Fenton BM
  4. Koch CJ
  5. Frelinger JG
  6. Keng PC
  7. Lord EM
  Alteration of tumour response to radiation by interleukin-2 gene transfer.; British journal of cancer; Vol 82(4). 2000 Feb.
• 1. Fenton BM
  2. Lord EM
  3. Paoni SF
  Enhancement of tumor perfusion and oxygenation by carbogen and nicotinamide during single- and multifraction irradiation.; Radiation research; Vol 153(1). 2000 Jan.
• 1. Storozynsky E
  2. Woodward JG
  3. Frelinger JG
  4. Lord EM
  Interleukin-3 and granulocyte-macrophage colony-stimulating factor enhance the generation and function of dendritic cells.; Immunology; Vol 97(1). 1999 May.
• 1. Fenton BM
  2. Paoni SF
  3. Lee J
  4. Koch CJ
  5. Lord EM
  Quantification of tumour vasculature and hypoxia by immunohistochemical staining and HbO2 saturation measurements.; British journal of cancer; Vol 79(3-4). 1999 Feb.
• 1. Wei C
  2. Callahan BP
  3. Turner MJ
  4. Willis RA
  5. Lord EM
  6. Barth RK
  7. Frelinger JG
  Regulation of human prostate-specific antigen gene expression in transgenic mice: evidence for an enhancer between the PSA and human glandular kallikrein-1 genes.; International journal of molecular medicine; Vol 2(4). 1998 Oct.
• 1. Yeh KY
  2. McAdam AJ
  3. Pulaski BA
  4. Shastri N
  5. Frelinger JG
  6. Lord EM
  IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes.; Journal of immunology (Baltimore, Md. : 1950); Vol 160(12). 1998 Jun 15.
• 1. Lord EM
  2. Yeh KY
  3. Moran JA
  4. Storozynsky E
  5. Frelinger JG
  IL-3-mediated enhancement of particulate antigen presentation by macrophages.; Journal of immunotherapy (Hagerstown, Md. : 1997); Vol 21(3). 1998 May.
• 1. Lord EM
  2. Frelinger JG
  Tumor immunotherapy: cytokines and antigen presentation.; Cancer immunology, immunotherapy : CII; Vol 46(2). 1998 Apr.
• 1. Lee J
  2. Fenton BM
  3. Koch CJ
  4. Frelinger JG
  5. Lord EM
  Interleukin 2 expression by tumor cells alters both the immune response and the tumor microenvironment.; Cancer research; Vol 58(7). 1998 Apr 1.
• 1. Willis RA
  2. Wei C
  3. Turner MJ
  4. Callahan BP
  5. Pugh AE
  6. Barth RK
  7. Lord EM
  8. Frelinger JG
  A transgenic strategy for analyzing the regulatory regions of the human prostate-specific antigen gene: potential applications for the treatment of prostate cancer (Review).; International journal of molecular medicine; Vol 1(2). 1998 Feb.
• 1. Fenton BM
  2. Paoni SF
  3. Koch CJ
  4. Lord EM
  Effect of local irradiation on tumor oxygenation, perfused vessel density, and development of hypoxia.; Advances in experimental medicine and biology; Vol 454. 1998.
• 1. Yeh KY
  2. Chen Z
  3. Nasir A
  4. Ohsuga Y
  5. Takashima A
  6. Lord EM
  7. Gaspari AA
  Expression of B7-1 by Pam 212 squamous cell carcinoma enhances tumor cell interactions with dendritic epidermal cells but does not affect in vivo tumor growth.; The Journal of investigative dermatology; Vol 109(6). 1997 Dec.
• 1. Wei C
  2. Willis RA
  3. Tilton BR
  4. Looney RJ
  5. Lord EM
  6. Barth RK
  7. Frelinger JG
  Tissue-specific expression of the human prostate-specific antigen gene in transgenic mice: implications for tolerance and immunotherapy.; Proceedings of the National Academy of Sciences of the United States of America; Vol 94(12). 1997 Jun 10.
• 1. Koch CJ
  2. Lord EM
  3. Shapiro IM
  4. Clyman RI
  5. Evans SM
  Imaging hypoxia and blood flow in normal tissues.; Advances in experimental medicine and biology; Vol 428. 1997.
• 1. Lee J
  2. Siemann DW
  3. Koch CJ
  4. Lord EM
  Direct relationship between radiobiological hypoxia in tumors and monoclonal antibody detection of EF5 cellular adducts.; International journal of cancer; Vol 67(3). 1996 Jul 29.
• 1. Wei C
  2. Storozynsky E
  3. McAdam AJ
  4. Yeh KY
  5. Tilton BR
  6. Willis RA
  7. Barth RK
  8. Looney RJ
  9. Lord EM
  10. Frelinger JG
  Expression of human prostate-specific antigen (PSA) in a mouse tumor cell line reduces tumorigenicity and elicits PSA-specific cytotoxic T lymphocytes.; Cancer immunology, immunotherapy : CII; Vol 42(6). 1996 Jul.
• 1. Pulaski BA
  2. Yeh KY
  3. Shastri N
  4. Maltby KM
  5. Penney DP
  6. Lord EM
  7. Frelinger JG
  Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex "re-presentation" of exogenous antigen by tumor-infiltrating antigen-presenting cells.; Proceedings of the National Academy of Sciences of the United States of America; Vol 93(8). 1996 Apr 16.
• 1. Woods ML
  2. Koch CJ
  3. Lord EM
  Detection of individual hypoxic cells in multicellular spheroids by flow cytometry using the 2-nitroimidazole, EF5, and monoclonal antibodies.; International journal of radiation oncology, biology, physics; Vol 34(1). 1996 Jan 1.
• 1. McAdam AJ
  2. Pulaski BA
  3. Storozynsky E
  4. Yeh KY
  5. Sickel JZ
  6. Frelinger JG
  7. Lord EM
  Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor.; Cellular immunology; Vol 165(2). 1995 Oct 15.
• 1. Yeh KY
  2. Pulaski BA
  3. Woods ML
  4. McAdam AJ
  5. Gaspari AA
  6. Frelinger JG
  7. Lord EM
  B7-1 enhances natural killer cell-mediated cytotoxicity and inhibits tumor growth of a poorly immunogenic murine carcinoma.; Cellular immunology; Vol 165(2). 1995 Oct 15.
• 1. McAdam AJ
  2. Pulaski BA
  3. Harkins SS
  4. Hutter EK
  5. Lord EM
  6. Frelinger JG
  Synergistic effects of co-expression of the TH1 cytokines IL-2 and IFN-gamma on generation of murine tumor-reactive cytotoxic cells.; International journal of cancer; Vol 61(5). 1995 May 29.
• 1. McAdam AJ
  2. Felcher A
  3. Woods ML
  4. Pulaski BA
  5. Hutter EK
  6. Frelinger JG
  7. Lord EM
  Transfection of transforming growth factor-beta producing tumor EMT6 with interleukin-2 elicits tumor rejection and tumor reactive cytotoxic T-lymphocytes.; Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy; Vol 15(3). 1994 Apr.
• 1. Woods ML
  2. McAdam AJ
  3. Frelinger JG
  4. Lord EM
  Isolation and expansion of tumor-infiltrating lymphocytes.; BioTechniques; Vol 15(6). 1993 Dec.
• 1. Lord EM
  2. Harwell L
  3. Koch CJ
  Detection of hypoxic cells by monoclonal antibody recognizing 2-nitroimidazole adducts.; Cancer research; Vol 53(23). 1993 Dec 1.
• 1. McAdam AJ
  2. Yeh KY
  3. Pulaski BA
  4. Frelinger JG
  5. Lord EM
  Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2.; Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy; Vol 14(4). 1993 Nov.
• 1. Chen Z
  2. Rosten SI
  3. Lord EM
  4. Gaspari AA
  Murine Pam 212 cutaneous squamous cell carcinoma is nonimmunogenic in normal syngeneic hosts and resistant to immune effector mechanisms.; Regional immunology; Vol 5(5). 1993 Sep.
• 1. Pulaski BA
  2. McAdam AJ
  3. Hutter EK
  4. Biggar S
  5. Lord EM
  6. Frelinger JG
  Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism.; Cancer research; Vol 53(9). 1993 May 1.
• 1. McAdam AJ
  2. Blieden TM
  3. Frelinger JG
  4. Lord EM
  CD4-class II major histocompatibility complex interaction does not enhance killing by a class I-restricted CD4+CD8+ cytotoxic T cell clone.; European journal of immunology; Vol 22(9). 1992 Sep.
• 1. Cerosaletti KM
  2. Woodward JG
  3. Lord EM
  4. Frelinger JG
  Two regions of the H-2 Dd promoter are responsive to dimethylsulfoxide in line 1 cells by a mechanism distinct from IFN-gamma.; Journal of immunology (Baltimore, Md. : 1950); Vol 148(4). 1992 Feb 15.
• 1. Blieden TM
  2. McAdam AJ
  3. Frelinger JG
  4. Lord EM
  Mechanism of cytolytic T lymphocyte killing of a low class I-expressing tumor.; Journal of immunology (Baltimore, Md. : 1950); Vol 147(4). 1991 Aug 15.
• 1. Blieden TM
  2. McAdam AJ
  3. Foresman MD
  4. Cerosaletti KM
  5. Frelinger JG
  6. Lord EM
  Class-I MHC expression in the mouse lung carcinoma, line 1: a model for class-I inducible tumors.; International journal of cancer. Supplement = Journal international du cancer. Supplement; Vol 6. 1991.
• 1. Cerosaletti KM
  2. Blieden TM
  3. Harwell LW
  4. Welsh KM
  5. Frelinger JG
  6. Lord EM
  Alteration of the metastatic potential of line 1 lung carcinoma cells: opposite effects of class I antigen induction by interferons versus DMSO or gene transfection.; Cellular immunology; Vol 127(2). 1990 May.
• 1. Wilson KM
  2. Siegal G
  3. Lord EM
  Tumor necrosis factor-mediated cytotoxicity by tumor-associated macrophages.; Cellular immunology; Vol 123(1). 1989 Oct 1.
• 1. Liu YC
  2. Marraccino RL
  3. Keng PC
  4. Bambara RA
  5. Lord EM
  6. Chou WG
  7. Zain SB
  Requirement for proliferating cell nuclear antigen expression during stages of the Chinese hamster ovary cell cycle.; Biochemistry; Vol 28(7). 1989 Apr 4.
• 1. Bahler DW
  2. Cerosaletti KM
  3. Lord EM
  4. Frelinger JG
  Molecular analysis of deficient class I H-2 antigen expression by mouse lung carcinoma cells.; Journal of immunology (Baltimore, Md. : 1950); Vol 140(11). 1988 Jun 1.
• 1. Marraccino RL
  2. Wahl AF
  3. Keng PC
  4. Lord EM
  5. Bambara RA
  Cell cycle dependent activities of DNA polymerases alpha and delta in Chinese hamster ovary cells.; Biochemistry; Vol 26(24). 1987 Dec 1.
• 1. Loeffler DA
  2. Keng PC
  3. Wilson KM
  4. Lord EM
  Comparison of fluorescence intensity of Hoechst 33342-stained EMT6 tumour cells and tumour-infiltrating host cells.; British journal of cancer; Vol 56(5). 1987 Nov.